Prognostic factors for metastatic gastrointestinal stromal tumors treated with cytoreductive surgery: a retrospective cohort study
Non-MP, R0/1 resection and mitotic index < 5/50 HPFs may predict better outcomes for patients with metastatic GISTs on imatinib, and CRS is feasible and safe.
Authors
- Zhaolun Cai (ORCID: https://orcid.org/0000-0002-3706-6703)
- Mingchun Mu (ORCID: https://orcid.org/0000-0003-0133-8882)
- Hai‐Ning Chen (ORCID: https://orcid.org/0000-0003-0104-8498)
- Yuan Yin (ORCID: https://orcid.org/0000-0002-0467-8092)
- Bo Zhang (ORCID: https://orcid.org/0000-0002-0254-5843)
- Chaoyong Shen (ORCID: https://orcid.org/0000-0002-8293-2746)
- Haidong Zhang (ORCID: https://orcid.org/0000-0003-2422-0182)
- Xiaonan Yin
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Scandinavian Journal of Gastroenterology
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1080/00365521.2025.2544312
- Primary Topic
- Gastrointestinal Tumor Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sichuan Province Science and Technology Support Program